Page 193 - Drug Class Review
P. 193

Drug Effectiveness Review Project
                                    Alzheimer classification: Mild to moderately severe
                                 Groups similar at baseline: Yes


                                        rivastigmine 1-4 mg/d   placebo  rivastigmine 6-12 mg/d   NR   NR   NR   NR   NR   NR   NR   NR   NR            23.29   23.57   23.87   54.1   55.22   53.8  Primary Outcome Measures:  ADAS-Cog; PDS; CIBIC  Secondary Outcome Measures: MMSE; GDS  Timing of assessments: Primary outcome measures at baseline and weeks 12, 18 and 26; secondary  outcome measures at baseline and week 26   Health Outcome Measures:  Scores on PDS improved in patients taking high dose RIV when compared with placebo, P < 0.05  (LOCF analysis); no significant difference observed between low dose RIV and placebo, P


















                                                                                            •         •            •         •     •














             Final Report Update 1     Authors: Rösler et al.   Year: 1999   POPULATION  CHARACTERISTICS:       Mean age (years):   Sex (% female):   Ethnicity:   Other germane population qualities:   Baseline ADAS-Cog   •   Baseline PDS    •     OUTCOME ASSESSMENT:          RESULTS:     Alzheimer's Drugs
   188   189   190   191   192   193   194   195   196   197   198